Ascendis Pharma A/S Stock News

COPENHAGEN, Denmark, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report second quarter 2023 financial results and provide a business update on Tuesday,

The mean of analysts' price targets for Ascendis Pharma A/S (ASND) points to a 47.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am

COPENHAGEN, Denmark, June 07, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice Presi

The US Food and Drug Administration (FDA) did not grant its approval to Ascendis Pharma's experimental hormone disorder therapy, but the company's stock has soared Monday nonetheless.  The therapy, c

Ascendis has seen a big uptake in sales for its human growth hormone therapy. The company said it plans to request a meeting with the FDA regarding hyperthyroidism therapy TransCon PTH.

Ascendis Pharma A/S (ASND) Q1 2023 Earnings Call Transcript.

Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.

We are upgrading from a hold to buy rating for ASND following a 35% drop in stock price after FDA deficiency findings in the NDA for TransCon PTH for hyperparathyroidism. We expect potential US FDA ap

COPENHAGEN, Denmark, April 13, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the company will hold a conference call and live webcast on Thursday, April 27, 2023, at

Ascendis Pharma A/S (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more

The FDA found deficiencies with Ascendis' regulatory filing for TransCon PTH in treating hypoparathyroidism. Ascendis plans to talk with the FDA to learn more about the issues and hopefully address th

Ascendis has enjoyed a market cap valuation of >$6bn thanks to its TransCon technology platform and single approved asset SKYTROFA. SKYTROFA is approved for growth hormone deficiency as a once-weekly

The FDA identifies deficiencies in Ascendis' (ASND) regulatory filing for TransCon PTH in hypoparathyroidism. This might lead to an extended review timeline of the company's filing.

The FDA has identified deficiencies in Ascendis' regulatory filing for the hypoparathyroidism candidate TransCon PTH. With little info on the nature of the deficiencies, investors are moving to the si

David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 20